MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.
As part of the collaboration, MedImmune will work with researchers at Manchester’s Centre of Excellence in Biopharmaceuticals (COEBP) on testing and understanding the fundamental principles of protein solution behavior in order to find better ways to administer breakthrough medicines to patients.